Why Did Jounce Therapeutics (JNCE) Stock Gain 72% Today?

Following an amendment in a strategic agreement, shares of Jounce Therapeutics Inc. (JNCE) increased 59.75% to $1.18 on Wednesday. Which agreement has JNCE amended? In an announcement made yesterday, Jounce Therapeutics (JNCE) stated that it has modified its current license arrangement with Gilead Sciences Inc. (GILD) for GS-1811 (formerly JTX-1811). Gilead will now be entitled […]

News RTS
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.